Humanized cobra venom factor decreases myocardial ischemia-reperfusion injury

Molecular Immunology

Volumn 47, Issue 2-3, 2009, Pages 506-510

  Gorsuch, W Brian ^a   Guikema, Benjamin J ^a   Fritzinger, David C ^b   Vogel, Carl Wilhelm ^b   Stahl, Gregory L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

Complement; Infarction; Inflammation

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COBROTOXIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; COMPLEMENT INHIBITOR; HC 3 1496; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; COMPLEMENT INHIBITION; CONTROLLED STUDY; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY;

ANIMALS; COBRA VENOMS; COMPLEMENT C3; COMPLEMENT C5; HUMANS; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

MUS;

EID: 70450223343     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2009.08.017     Document Type: Article

References (27)

1. Armstrong P.W., Mahaffey K.W., Chang W.C., Weaver W.D., Hochman J.S., Theroux P., Rollins S., Todaro T.G., Granger C.B., and COMMA Investigators. Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction. Am. Heart J. 151 (2006) 787-790
2. Buerke M., Murohara T., and Lefer A.M. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 91 (1995) 393-402
3. Busche M.N., Walsh M.C., McMullen M.E., Guikema B.J., and Stahl G.L. Mannose-binding lectin plays a critical role in myocardial ischaemia and reperfusion injury in a mouse model of diabetes. Diabetologia 51 (2008) 1544-1551
4. Crawford M.H., Grover F.L., Kolb W.P., McMahan C.A., O'Rourke R.A., McManus L.M., and Pinckard R.N. Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circ. Res. 78 (1988) 1449-1458
5. Fritzinger D.C., Hew B.E., Lee J.Q., Newhouse J., Alam M., Ciallella J.R., Bowers M., Gorsuch W.B., Guikema B.J., Stahl G.L., and Vogel C.W. Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents. Adv. Exp. Med. Biol. 632 (2008) 293-307
6. Fritzinger D.C., Hew B.E., Lee J.Q., St. John W., Scaife M., Wilson S., and Vogel C.-W. Human C3/cobra venom factor hybrid proteins for therapeutic complement depletion: in vivo activity and lack of toxicity in primates. Mol. Immunol. 45 (2008) 4112
7. Fritzinger D.C., Hew B.E., Thorne M., Pangburn M.K., Janssen B.J., Gros P., and Vogel C.W. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion. Dev. Comp. Immunol. 33 (2009) 105-116
8. x structures. Glycobiology 11 (2001) 195-208
9. Gowda D.C., Petrella E.C., Raj T.T., Bredehorst R., and Vogel C.-W. Immunoreactivity and function of oligosaccharides in cobra venom factor. J. Immunol. 152 (1994) 2977-2986
10. Granger C.B., Mahaffey K.W., Weaver W.D., Theroux P., Hochman J.S., Filloon T.G., Rollins S., Todaro T.G., Nicolau J.C., Ruzyllo W., and Armstrong P.W. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 108 (2003) 1184-1190
11. Hart M.L., Ceonzo K.A., Shaffer L.A., Takahashi K., Rother R.P., Reenstra W.R., Buras J.A., and Stahl G.L. Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. J. Immunol. 174 (2005) 6373-6380
12. Hill J.H., and Ward P.A. The phlogistic role of C3 leukotactic fragments in myocardial infarcts in rats. J. Exp. Med. 133 (1971) 885-900
13. Jordan J.E., Montalto M.C., and Stahl G.L. Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 104 (2001) 1413-1418
14. Kenchaiah S., Pfeffer M.A., St. John Sutton M., Plappert T., Rouleau J.L., Lamas G.A., Sasson Z., Parker J.O., Geltman E.M., and Solomon S.D. Effect of antecedent systemic hypertension on subsequent left ventricular dilation after acute myocardial infarction (from the Survival and Ventricular Enlargement trial). Am. J. Cardiol. 94 (2004) 1-8
15. MacLean D., Fishbein M.C., Braunwald E., and Maroko P.R. Long-term preservation of ischemic myocardium after experimental coronary artery occlusion. J. Clin. Invest. 61 (1978) 541-551
16. Maroko P.R., Carpenter C.B., Chiariello M., Fishbein M.C., Radvany P., Knostman J.D., and Hale S.L. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J. Clin. Invest. 61 (1978) 661-670
17. Pinckard R.N., O'Rourke R.A., Crawford M.H., Grover F.S., McManus L.M., Ghidoni J.J., Storrs S.B., and Olson M.S. Complement localization and mediation of ischemic injury in baboon myocardium. J. Clin. Invest. 66 (1980) 1050-1056
18. Sahn D.J., DeMaria A., Kisslo J., and Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58 (1978) 1072-1083
19. Stahl G.L., Xu Y., Hao L., Miller M., Buras J.A., Fung M., and Zhao H. Role for the alternative complement pathway in ischemia/reperfusion injury. Am. J. Pathol. 162 (2003) 455
20. Vakeva A.P., Agah A., Rollins S.A., Matis L.A., Li L., and Stahl G.L. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 97 (1998) 2259-2267
21. Vogel C.W., and Fritzinger D.C. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion. Curr. Pharm. Des. 13 (2007) 2916-2926
22. Vogel C.W., and Muller-Eberhard H.J. Cobra venom factor: improved method for purification and biochemical characterization. J. Immunol. Meth. 73 (1984) 203-220
23. Vogel C.-W. Cobra venom factor, the complement-activating protein of cobra venom. In: Tu A.T. (Ed). Handbook of Natural Toxins: Reptile and Amphibian Venoms (1991), Marcel Dekker, New York 147-188
24. Walport M.J. Complement. First of two parts. N. Engl. J. Med 344 (2001) 1058-1066
25. Walport M.J. Complement. Second of two parts. N. Engl. J. Med 344 (2001) 1140-1144
26. Walsh M.C., Bourcier T., Takahashi K., Shi L., Busche M.N., Rother R.P., Solomon S.D., Ezekowitz R.A., and Stahl G.L. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J. Immunol. 175 (2005) 541-546
27. Weisman H.F., Bartow T., Leppo M.K., Marsh Jr. H.C.J., Carson G.R., Concino M.F., Boyle M.P., Roux K.H., Weisfeldt M.L., and Fearon D.T. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249 (1990) 146-151